In our study, we used the most validated murine model of FD (GLA−/− mouse) at both early and advanced stages of the disease.13,27 We tested 2 pharmacological interventions: minocycline, a microglial inhibitor, and PC1 (patented compound 1), a specific antagonist of the chemokine prokineticin-2 (PK2). This evidence concerns the gene PROK2 and Fabry disease.